West Pharmaceutical Services (NYSE:WST) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.90. The company issued revenue guidance of $1.72-1.73 billion, compared to the consensus revenue estimate of $1.73 billion.
Several research firms have recently weighed in on WST. Goldman Sachs Group began coverage on West Pharmaceutical Services in a research note on Wednesday, January 24th. They set a neutral rating and a $110.00 price objective for the company. Zacks Investment Research lowered West Pharmaceutical Services from a hold rating to a sell rating in a research note on Saturday, January 6th. Finally, Wells Fargo & Co raised their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an outperform rating in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services has a consensus rating of Hold and a consensus target price of $108.17.
Shares of West Pharmaceutical Services (WST) opened at $89.82 on Thursday. The stock has a market capitalization of $6,905.52, a price-to-earnings ratio of 40.09, a PEG ratio of 1.97 and a beta of 1.04. West Pharmaceutical Services has a 1-year low of $77.97 and a 1-year high of $103.36. The company has a quick ratio of 1.87, a current ratio of 2.59 and a debt-to-equity ratio of 0.15.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Thursday, January 18th were issued a $0.14 dividend. The ex-dividend date of this dividend was Wednesday, January 17th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.62%. West Pharmaceutical Services’s payout ratio is currently 22.31%.
In other news, CFO William J. Federici sold 21,000 shares of the stock in a transaction on Friday, December 8th. The stock was sold at an average price of $99.01, for a total value of $2,079,210.00. Following the completion of the sale, the chief financial officer now owns 190,493 shares in the company, valued at $18,860,711.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/15/west-pharmaceutical-services-wst-releases-fy18-earnings-guidance.html.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.